

## HalioDx strengthens its Management Team

- Stéphane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
- Philippe Mourere joins the Executive Committee as SVP Commercial and Business Development

Marseille, France, July 16, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced a change in its leadership team with the appointment of Stéphane Debono as Deputy CEO and of Philippe Mourere as Senior Vice President Commercial and Business Development.

Stéphane Debono brings more than 25 years of experience in the IVD Industry. He becomes Deputy CEO of HalioDx. Stéphane Debono is a co-founder of HalioDx, and with his expanded responsibilities will now oversee the daily operations and growth of HalioDx.

Philippe Mourere brings over 20 years of experience as a senior sales, marketing and business development executive from both large and mid-size global Life Science companies, with a focus on growth strategies in highly specialized genomics, proteomics, personalized medicine and digital pathology markets. US-based, he will lead commercial and business development with an immediate concentration on the US expansion of HalioDx Pharma & Diagnostic Businesses.

In his most recent positions, Philippe Mourere was Sr. Vice President Commercial Operations at Ultivue, a developer of tissue biomarker assays for translational research where he had a major role in developing and executing full commercialization strategy of the company, actively participating to the growth of multiplexed tissue marker immuno-profiling business.

**Vincent Fert, Chairman and CEO of HalioDx, said** *“I have been working with Stéphane for 20 years; his comprehensive and successful IVD experience, his business acumen and strong leadership style is the perfect skill-set to lead HalioDx international operations to the next level. Philippe brings us a strong track record in driving value-generating business development initiatives and in commercial operations that will complement our leadership team. Over the past 5 years, HalioDx has continuously delivered above expectations, and we are planning to accelerate our growth in the next years, with a special focus on the commercial execution notably in the US market”.*

\*\*\*

### About HalioDx

#### The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immunotherapy and combination therapies.

Thanks to the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions - notably with the flagship Immunoscore® assay - allowing the assessment of the immune contexture of tumor, a key determinant of patients' outcomes and response to cancer treatments (from preclinical stage to approved therapies).

To address the needs of Biopharmas, HaliODx has developed customized services to guide clinical programs and help to predict patient response to immunotherapy, with a unique approach to the TME exploration (TMEExplore™) including innovative technologies such as Multiplex Spatial Tissue Analysis (Brightplex®), molecular testing (NGS, Immunosign® Gene Expression Signatures), that are the pillars of the multimodal analysis platform, Immunogram, and of the building of a comprehensive database that collect and analyze results from a unique compendium of biomarkers and phenotypes on large cohorts of patients for each cancer indication : the cancer immune Atlas.

HaliODx has an experienced team of more than 170 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

**For more information, please visit our websites [www.haliidx.com](http://www.haliidx.com) and [www.immunoscore-colon.com](http://www.immunoscore-colon.com) and follow the company on [Twitter](#), [Linkedin](#) and [Youtube](#).**

*Immunoscore® is a registered trademark of Inserm licenced to HaliODx. Brightplex®, TMEExplore™ and Immunosign® are registered trademarks of HaliODx.*

## Contacts

### **Vincent Fert**

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@haliidx.com](mailto:vincent.fert@haliidx.com)

### **ATCG Partners**

Marie Puvieux / Céline Voisin

+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39

[haliidx@atcg-partners.com](mailto:haliidx@atcg-partners.com)